Literature DB >> 31865800

Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy.

Sjoerd A M E G Timmermans1,2, Alexis Wérion3, Jan G M C Damoiseaux4, Johann Morelle3,5, Chris P Reutelingsperger2, Pieter van Paassen1,2.   

Abstract

Hypertensive emergency can cause thrombotic microangiopathy (TMA) in the kidneys with high rates of end-stage renal disease (ESRD) and vice versa. The conundrum of hypertension as the cause of TMA or consequence of TMA on the background of defects in complement regulation remains difficult. Patients with hypertensive emergency and TMA on kidney biopsy were tested for ex vivo C5b9 formation on the endothelium and rare variants in complement genes to identify complement-mediated TMA. We identified factors associated with defects in complement regulation and poor renal outcomes. Massive ex vivo C5b9 formation was found on resting endothelial cells in 18 (69%) out of 26 cases at the presentation, including the 9 patients who carried at least one rare genetic variant. Thirteen (72%, N=18) and 3 (38%, N=8) patients with massive and normal ex vivo complement activation, respectively, progressed to ESRD (P=0.03). In contrast to BP control, inhibition of C5 activation prevented ESRD to occur in 5 (83%, N=6) patients with massive ex vivo complement activation. TMA-related graft failure occurred in 7 (47%, N=15) donor kidneys and was linked to genetic variants. The assessment of both ex vivo C5b9 formation and screening for rare variants in complement genes may categorize patients with hypertensive emergency and TMA into different groups with potential therapeutic and prognostic implications. We propose an algorithm to recognize patients at the highest risk for defects in complement regulation.

Entities:  

Keywords:  atypical hemolytic uremic syndrome; biopsy; complement; endothelium; thrombotic microangiopathies

Mesh:

Substances:

Year:  2019        PMID: 31865800     DOI: 10.1161/HYPERTENSIONAHA.119.13714

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  16 in total

Review 1.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

2.  The potential role of complement alternative pathway activation in hypertensive renal damage.

Authors:  Chongjian Wang; Zhiyu Wang; Wen Zhang
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-27

3.  C5 Inhibition in Secondary Thrombotic Microangiopathies: A Yet Unresolved Question.

Authors:  Alexis Werion; Eric Rondeau
Journal:  Kidney Int Rep       Date:  2021-02-22

Review 4.  Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.

Authors:  Jacob J E Koopman; Mieke F van Essen; Helmut G Rennke; Aiko P J de Vries; Cees van Kooten
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

5.  Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes.

Authors:  Sjoerd A M E G Timmermans; Jan G M C Damoiseaux; Alexis Werion; Chris P Reutelingsperger; Johann Morelle; Pieter van Paassen
Journal:  Kidney Int Rep       Date:  2021-02-03

Review 6.  Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review.

Authors:  Edward J Filippone; Eric D Newman; Li Li; Rakesh Gulati; John L Farber
Journal:  Front Immunol       Date:  2021-11-10       Impact factor: 7.561

Review 7.  Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes.

Authors:  Renaud Prével; Yahsou Delmas; Vivien Guillotin; Didier Gruson; Etienne Rivière
Journal:  J Clin Med       Date:  2022-02-01       Impact factor: 4.241

Review 8.  Ex Vivo Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside.

Authors:  Marie-Sophie Meuleman; Anna Duval; Véronique Fremeaux-Bacchi; Lubka T Roumenina; Sophie Chauvet
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

Review 9.  Complement in Secondary Thrombotic Microangiopathy.

Authors:  Lilian Monteiro Pereira Palma; Meera Sridharan; Sanjeev Sethi
Journal:  Kidney Int Rep       Date:  2020-10-21

Review 10.  TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities.

Authors:  Kun-Hua Tu; Pei-Yi Fan; Tai-Di Chen; Wen-Yu Chuang; Chao-Yi Wu; Cheng-Lung Ku; Ya-Chung Tian; Chih-Wei Yang; Ji-Tseng Fang; Huang-Yu Yang
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.